MRK - Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
Deals and Financings
VistaGen (VTGN) of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement. VistaGen's PH94B is a rapid-onset neurosteroid drug candidate for multiple anxiety-related disorders that is ready for Phase III trials. It has received US Fast Track designation to treat social anxiety disorder ((SAD)). The collaboration between the companies will support Phase III development and commercialization of PH94B in China/Asia markets. ChinaBio advised VistaGen on the transaction.
Beijing's SinocellTech (SHA: 688520) completed a $181 million IPO on